The most common side effects are joint and muscle pain in the arms or legs. There is an increased risk of infections such as cellulitis, hypocalcemia (low blood calcium), hypersensitivity allergy reactions, osteonecrosis of the jaw, and atypical femur fractures. Another trial showed significantly increased rates of eczema and hospitalization due to infections of the skin. It has been proposed that the increase in infections under<unk>  treatment might be connected to the role of RANKL in the immune system. RANKL is expressed by T helper cells, and is thought to be involved in dendritic cell maturation. Discontinuation of<unk>  is associated with a rebound increase in bone turnover. In rare cases this has led to severe hypercalcemia, especially in children. Vertebral compression fractures have also occurred in some people after discontinuing treatment.
Denosumab
Medronic acid
Zoledronic acid
Alendronic acid
Risedronic acid
Teriparatide
Pamidronic acid
Ibandronic acid